In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

NCT00631072 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL: INKT
DRUG: GM-CSF

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]